Literature DB >> 11042238

Management and dosing of warfarin therapy.

B F Gage1, S D Fihn, R H White.   

Abstract

When initiating warfarin therapy, clinicians should avoid loading doses that can raise the International Normalized Ratio (INR) excessively; instead, warfarin should be initiated with a 5-mg dose (or 2 to 4 mg in the very elderly). With a 5-mg initial dose, the INR will not rise appreciably in the first 24 hours, except in rare patients who will ultimately require a very small daily dose (0.5 to 2.0 mg). Adjusting a steady-state warfarin dose depends on the measured INR values and clinical factors: the dose does not need to be adjusted for a single INR that is slightly out of range, and most changes should alter the total weekly dose by 5% to 20%. The INR should be monitored frequently (eg, 2 to 4 times per week) immediately after initiation of warfarin; subsequently, the interval between INR tests can be lengthened gradually (up to a maximum of 4 to 6 weeks) in patients with stable INR values. Patients who have an elevated INR will need more frequent testing and may also require vitamin K1. For example, a nonbleeding patient with an INR of 9 can be given low-dose vitamin K1 (eg, 2.5 mg phytonadione, by mouth). Patients who have an excessive INR with clinically important bleeding require clotting factors (eg, fresh-frozen plasma) as well as vitamin K1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042238     DOI: 10.1016/s0002-9343(00)00545-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  26 in total

1.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

Authors:  M A Perera; E Gamazon; L H Cavallari; S R Patel; S Poindexter; R A Kittles; D Nicolae; N J Cox
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 3.  Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation.

Authors:  G Eymin; A K Jaffer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

4.  Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.

Authors:  Edith A Nutescu; Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

5.  Use of intravenous recombinant tissue plasminogen activator in patients with borderline elevation of international normalized ratio.

Authors:  Harsh R Aggarwal; Ameer E Hassan; Gustavo J Rodriguez; M Fareed K Suri; Robert A Taylor; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2013-12

6.  Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.

Authors:  Alexander Mensch; Stephanie Stock; Björn Stollenwerk; Dirk Müller
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

7.  Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France.

Authors:  Marc Ruivard; Christine Berger; Abdellaziz Achaibi; Claude Campagne; Pierre Philippe
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

Review 8.  Treatment of deep vein thrombosis: what factors determine appropriate treatment?

Authors:  James D Douketis
Journal:  Can Fam Physician       Date:  2005-02       Impact factor: 3.275

9.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

10.  Conventional oral anticoagulation may not replace prior transesophageal echocardiography for the patients with planned catheter ablation for atrial fibrillation.

Authors:  Hua He; Junping Kang; Hailong Tao; Bin Zhen; Ming Zhang; Deyong Long; Jianzeng Dong
Journal:  J Interv Card Electrophysiol       Date:  2008-11-04       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.